A Consensus Molecular Classification of Muscle-invasive Bladder Cancer

Muscle-invasive bladder cancer (MIBC) is a molecularly diverse disease with heterogeneous clinical outcomes. Several molecular classifications have been proposed, but the diversity of their subtype sets impedes their clinical application. To achieve an international consensus on MIBC molecular subty...

Celý popis

Uložené v:
Podrobná bibliografia
Vydané v:European urology Ročník 77; číslo 4; s. 420 - 433
Hlavní autori: Kamoun, Aurélie, de Reyniès, Aurélien, Allory, Yves, Sjödahl, Gottfrid, Robertson, A. Gordon, Seiler, Roland, Hoadley, Katherine A., Groeneveld, Clarice S., Al-Ahmadie, Hikmat, Choi, Woonyoung, Castro, Mauro A.A., Fontugne, Jacqueline, Eriksson, Pontus, Mo, Qianxing, Kardos, Jordan, Zlotta, Alexandre, Hartmann, Arndt, Dinney, Colin P., Bellmunt, Joaquim, Powles, Thomas, Malats, Núria, Chan, Keith S., Kim, William Y., McConkey, David J., Black, Peter C., Dyrskjøt, Lars, Höglund, Mattias, Lerner, Seth P., Real, Francisco X., Radvanyi, François, Aine, Mattias, Bernard-Pierrot, Isabelle, Czerniak, Bogdan, Gibb, Ewan A., Kim, Jaegil, Kwiatkowski, David J., Lebret, Thierry, Liedberg, Fredrik, Siefker-Radtke, Arlene, Sirab, Nanor, Taber, Ann, Weinstein, John
Médium: Journal Article
Jazyk:English
Vydavateľské údaje: Switzerland Elsevier B.V 01.04.2020
Elsevier
Predmet:
ISSN:0302-2838, 1873-7560, 1421-993X, 1873-7560, 1421-993X
On-line prístup:Získať plný text
Tagy: Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
Popis
Shrnutí:Muscle-invasive bladder cancer (MIBC) is a molecularly diverse disease with heterogeneous clinical outcomes. Several molecular classifications have been proposed, but the diversity of their subtype sets impedes their clinical application. To achieve an international consensus on MIBC molecular subtypes that reconciles the published classification schemes. We used 1750 MIBC transcriptomic profiles from 16 published datasets and two additional cohorts. We performed a network-based analysis of six independent MIBC classification systems to identify a consensus set of molecular classes. Association with survival was assessed using multivariable Cox models. We report the results of an international effort to reach a consensus on MIBC molecular subtypes. We identified a consensus set of six molecular classes: luminal papillary (24%), luminal nonspecified (8%), luminal unstable (15%), stroma-rich (15%), basal/squamous (35%), and neuroendocrine-like (3%). These consensus classes differ regarding underlying oncogenic mechanisms, infiltration by immune and stromal cells, and histological and clinical characteristics, including outcomes. We provide a single-sample classifier that assigns a consensus class label to a tumor sample’s transcriptome. Limitations of the work are retrospective clinical data collection and a lack of complete information regarding patient treatment. This consensus system offers a robust framework that will enable testing and validation of predictive biomarkers in future prospective clinical trials. Bladder cancers are heterogeneous at the molecular level, and scientists have proposed several classifications into sets of molecular classes. While these classifications may be useful to stratify patients for prognosis or response to treatment, a consensus classification would facilitate the clinical use of molecular classes. Conducted by multidisciplinary expert teams in the field, this study proposes such a consensus and provides a tool for applying the consensus classification in the clinical setting. An international consortium of bladder cancer expert teams establishes a consensus reconciling the diverse molecular classifications of muscle-invasive bladder cancer. This work offers a robust framework that will enable testing and validating predictive biomarkers in future prospective clinical trials.
Bibliografia:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Study concept and design: Kamoun, de Reyniès, Allory, Sjödahl, Robertson, Seiler, Hoadley, Al-Ahmadie, Choi, Groeneveld, Castro, Fontugne, Eriksson, Mo, Kardos, Zlotta, Hartmann, Dinney, Bellmunt, Powles, Malats, Chan, Kim, McConkey, Black, Dyrskjøt, Höglund, Lerner, Real, Radvanyi, the Bladder Cancer Molecular Taxonomy Group.
Critical revision of the manuscript for important intellectual content: Kamoun, de Reyniès, Allory, Sjödahl, Robertson, Seiler, Hoadley, Al-Ahmadie, Choi, Groeneveld, Castro, Fontugne, Eriksson, Mo, Kardos, Zlotta, Hartmann, Dinney, Bellmunt, Powles, Malats, Chan, Kim, McConkey, Black, Dyrskjøt, Höglund, Lerner, Real, Radvanyi, the Bladder Cancer Molecular Taxonomy Group.
These authors contributed equally to this work.
Administrative, technical, or material support: None.
Other: F.X. Real initiated the consensus effort.
Supervision: Allory, de Reyniès, Real, Radvanyi.
Acquisition of data: Allory, Sjödahl, Seiler, Fontugne, Black, Dyrskjøt. Analysis and interpretation of data: Kamoun, de Reyniès, Hoadley, Groeneveld, Castro, Fontugne.
Statistical analysis: Kamoun, de Reyniès, Sjödahl, Mo, Kardos, Choi, Hoadley.
Author contributions: Aurélie Kamoun had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
A full list of all consortium members appears in Appendix 1.
Obtaining funding: None.
Drafting of the manuscript: Kamoun, de Reyniès, Allory, Sjödahl, Robertson, Dyrskjøt, Höglund, Real, Radvanyi.
ISSN:0302-2838
1873-7560
1421-993X
1873-7560
1421-993X
DOI:10.1016/j.eururo.2019.09.006